Faron Pharmaceuticals Oy (FARON)
Helsinki Exchange · Finland · prices in EUR · close of 23 Oct 2026
Key indicators
| Last close | EUR 0.377 |
|---|---|
| 52-week range | 0.374 – 2.430 |
| Return, 1 month / 3 months | −10.1% / −23.2% |
| Return, 1 year / 3 years | −81.3% / −88.8% |
| Trend | Below its 200-day average |
| RSI (14) | 34 |
| Volatility (1 year) | 108.1% |
| Worst drawdown (1 year) | -84.3% |
| Average daily value traded | 0.27M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company based in Finland. It develops immunotherapies designed to influence the tumour microenvironment, concentrating on macrophage biology to help the body's immune system attack cancer. Its main investigational product is an antibody aimed at a receptor found on certain immune cells, studied in patients with advanced cancers. The company also has earlier work in acute and inflammatory conditions. Its activities centre on drug discovery, clinical development and related research partnerships.
The shares are listed on the Helsinki Exchange in Finland under the code FARON, and the price on this page is in euros (EUR). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Faron Pharmaceuticals Oy (FARON) trades on the Helsinki Exchange in Finland. It last closed at EUR 0.377 on 23 October 2026.
Its price-based Market X-Ray is 15 out of 100 (a weak price profile), ranking 180 of 190 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 81.3% and over the last three months it fell 23.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Helsinki Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 3 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -41.5% | ||
| From 52-week high | -84.3% | ||
| Momentum | 8 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -23.2% | ||
| 6-month return | -20.7% | ||
| 12-month return, skipping the last month | -79.2% | ||
| Stability (higher is calmer) | 2 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 108.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -84.3% | ||
| Liquidity | 67 · Fair | Moderate trading activity. | |
| Average daily value traded | 0.27M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | −5.0% |
|---|---|
| 1 month | −10.1% |
| 3 months | −23.2% |
| 6 months | −20.7% |
| 1 year | −81.3% |
| 3 years | −88.8% |
| 5 years | −90.7% |
Signals
| 50-day / 200-day average | 0.425 / 0.643 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.017 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Helsinki Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.